Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

被引：49

作者：

Adiwijaya, B. S. ^{[1
]}

Kim, J. ^{[1
]}

Lang, I. ^{[2
]}

Csoszi, T. ^{[3
]}

Cubillo, A. ^{[4
]}

Chen, J-S ^{[5
]}

Wong, M. ^{[6
]}

Park, J. O. ^{[7
]}

Kim, J. S. ^{[8
]}

Rau, K. M. ^{[9
]}

Melichar, B. ^{[10
]}

Gallego, J. B. ^{[11
]}

Fitzgerald, J. ^{[1
]}

Belanger, B. ^{[1
]}

Molnar, I. ^{[1
]}

Ma, W. W. ^{[12
]}

机构：

[1] Merrimack Pharmaceut Inc, Cambridge, MA 02139 USA

[2] Natl Inst Oncol, Budapest, Hungary

[3] JNSZ Megyei Hetenyi Geza Korhaz Rendelointezet, Szolnok, Hungary

[4] Ctr Integral Oncol Clara Campal, Madrid, Spain

[5] Chang Gung Mem Hosp, Linkou Branch, Taoyuan, Taiwan

[6] Westmead Hosp, Westmead, NSW, Australia

[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] Korea Univ, Guro Hosp, Seoul, South Korea

[9] Chang Gung Mem Hosp, Kaohsiung Branch, Kaohsiung, Taiwan

[10] Univ Palackeho, Onkol Klin, Lekarska Fak, Fak Nemocnice, Olomouc, Czech Republic

[11] Hosp Gen Elche, Elche, Spain

[12] Mayo Clin, Rochester, MN USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 06期

关键词：

INDUCED LIVER-INJURY; HEART-FAILURE; MECHANISTIC MODEL; CELL-DEATH; HEPATOTOXICITY; DYSFUNCTION; TOXICITY; PREVALENCE; BIOMARKERS; DILISYM(R);

D O I：

10.1002/cpt.720

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t(1/2)), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (C-max) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for neutropenia and diarrhea in 353 patients. PK-efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN-38 (uSN38) above a threshold and higher C-avg of tIRI, tSN38, and uSN38. Neutropenia was associated with uSN38 C-max and diarrhea with tIRI C-max. Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal-IRI dose of 70mg/m(2) (free-base; equivalent to 80mg/m(2) salt base) Q2W over 100mg/m(2) Q3W.

引用

页码：997 / 1005

页数：9

共 34 条

[1]

Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital [J].

Antoine, Daniel J. ;

Dear, James W. ;

Lewis, Philip Starkey ;

Platt, Vivien ;

Coyle, Judy ;

Masson, Moyra ;

Thanacoody, Ruben H. ;

Gray, Alasdair J. ;

Webb, David J. ;

Moggs, Jonathan G. ;

Bateman, D. Nicholas ;

Goldring, Christopher E. ;

Park, B. Kevin .

HEPATOLOGY, 2013, 58 (02) :777-787

[2]

RETRACTED: Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity (Publication with Expression of Concern. See vol. 73, pg. 1297, 2020) (Publication with Expression of Concern. See vol. 69, pg. 1402, 2018) (Retracted article. See vol. 73, pg. 1297, 2020) [J].

Antoine, Daniel J. ;

Jenkins, Rosalind E. ;

Dear, James W. ;

Williams, Dominic P. ;

McGill, Mitchell R. ;

Sharpe, Matthew R. ;

Craig, Darren G. ;

Simpson, Kenneth J. ;

Jaeschke, Hartmut ;

Park, B. Kevin .

JOURNAL OF HEPATOLOGY, 2012, 56 (05) :1070-1079

[3]

Boyd J W, 1983, Vet Clin Pathol, V12, P9, DOI 10.1111/j.1939-165X.1983.tb00609.x

[4]

Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon? [J].

Clarke, Joanna I. ;

Dear, James W. ;

Antoine, Daniel J. .

EXPERT OPINION ON DRUG SAFETY, 2016, 15 (05) :625-634

[5]

Clinical P, 2009, GUIDANCE IND DRUG IN

[6]

DAVIDSON AR, 1976, SCAND J GASTROENTERO, V11, P623

[7]

The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers [J].

Harrill, A. H. ;

Roach, J. ;

Fier, I. ;

Eaddy, J. S. ;

Kurtz, C. L. ;

Antoine, D. J. ;

Spencer, D. M. ;

Kishimoto, T. K. ;

Pisetsky, D. S. ;

Park, B. K. ;

Watkins, P. B. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (02) :214-220

[8]

A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial [J].

Howell, B. A. ;

Siler, S. Q. ;

Shoda, L. K. M. ;

Yang, Y. ;

Woodhead, J. L. ;

Watkins, P. B. .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (02)

[9]

Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18 [J].

Kramer, G ;

Erdal, H ;

Mertens, HJMM ;

Nap, M ;

Mauermann, J ;

Steiner, G ;

Marberger, M ;

Bivén, K ;

Shoshan, MC ;

Linder, S .

CANCER RESEARCH, 2004, 64 (05) :1751-1756

[10]

Circulating MicroRNAs as Potential Markers of Human Drug-Induced Liver Injury [J].

Lewis, Philip J. Starkey ;

Dear, James ;

Platt, Vivien ;

Simpson, Kenneth J. ;

Craig, Darren G. N. ;

Antoine, Daniel J. ;

French, Neil S. ;

Dhaun, Neeraj ;

Webb, David J. ;

Costello, Eithne M. ;

Neoptolemos, John P. ;

Moggs, Jonathan ;

Goldring, Chris E. ;

Park, B. Kevin .

HEPATOLOGY, 2011, 54 (05) :1767-1776

← 1 2 3 4 →